



DOSING AND ADMINISTRATION FOR ADULT AND PEDIATRIC PATIENTS

INDICATION

VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥ 1.5 kg), who are:

- Hospitalized, or
- Not hospitalized, have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

IMPORTANT SAFETY INFORMATION


Contraindication

- VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components.


Please see full [Prescribing Information](#) for Veklury.

Recommended dosing¹

For adult and pediatric patients weighing ≥ 40 kg




For pediatric patients ≥ 28 days old and weighing ≥ 3 kg to < 40 kg



For pediatric patients (including term* neonates and infants)

Pediatric patients from birth to < 28 days old and weighing ≥ 1.5 kg, and pediatric patients ≥ 28 days old and weighing 1.5 kg to < 3 kg should receive:



For those weighing ≥ 1.5 kg to < 40 kg, a small 0.9% sodium chloride injection infusion bag (eg, 25 mL, 50 mL, or 100 mL) or an appropriately sized syringe should be used for pediatric dosing. A syringe and syringe pump may be used for infusion volumes < 50 mL.

*Gestational age > 37 weeks.

VEKLURY can be administered in patients with renal or hepatic impairment¹



The only antiviral approved for patients with COVID-19 and **any stage of renal disease**

- NO dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment severity (eg, any eGFR), including dialysis
- NO renal laboratory testing is required before or during treatment



Patients with COVID-19 and **any stage of hepatic impairment**

- NO dosage adjustment of VEKLURY is recommended for patients with mild, moderate, or severe hepatic impairment
- Perform hepatic laboratory and prothrombin time testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and precautions

- **Hypersensitivity, including infusion-related and anaphylactic reactions:** Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of VEKLURY; most reactions occurred within 1 hour. Monitor patients during infusion and observe for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time of up to 120 minutes) can potentially prevent these reactions. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue VEKLURY and initiate appropriate treatment (see Contraindications).

Please see full [Prescribing Information for Veklury](#).

Recommended treatment duration¹

Recommended total duration for adult and pediatric patients, from birth and weighing ≥ 1.5 kg, who are NOT HOSPITALIZED

3
days

For patients who are **not** hospitalized, have mild-to-moderate COVID-19, and are at high risk for disease progression^{*}

Recommended total duration for adult and pediatric patients, from birth and weighing ≥ 1.5 kg, who are HOSPITALIZED

5
days

For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO

If a patient does not demonstrate clinical improvement, treatment may be extended up to 5 additional days, for a total treatment duration of up to 10 days

10
days

For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO

^{*}Disease progression includes hospitalization or death. Risk factors for progression include age ≥ 60 years, obesity (BMI ≥ 30 kg/m²), chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes mellitus, immunocompromised state, chronic mild or moderate kidney disease, chronic liver disease, current cancer, and sickle cell disease.

ECMO=extracorporeal membrane oxygenation.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and precautions (cont'd)

- **Increased risk of transaminase elevations:**
Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing in all patients (see Dosage and administration). Consider discontinuing VEKLURY if ALT levels increase to $>10x$ ULN. Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation.
- **Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine:** Coadministration of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments, demonstrating potential antagonism, which may lead to a decrease in the antiviral activity of VEKLURY.

Adverse reactions

- The most common adverse reaction ($\geq 5\%$ all grades) was nausea.
- The most common lab abnormalities ($\geq 5\%$ all grades) were increases in ALT and AST.

Dosage and administration

- Administration should take place under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible.
- **Treatment duration:**
 - For patients who **are hospitalized**, VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19.

Please see full [Prescribing Information for Veklury](#).

Preparation for infusion¹



Product appearance

- VEKLURY for injection, 100 mg, is a sterile, preservative-free, **white to off-white to yellow lyophilized powder**—color does not affect product stability—in a single-dose, clear glass vial
- Red cap on vial



Dose preparation

- VEKLURY for injection, 100 mg, lyophilized powder, must be reconstituted with 19 mL Sterile Water for Injection and diluted with 0.9% sodium chloride injection prior to administration
- For pediatric patients (birth to <18 years of age) weighing 1.5 kg to <40 kg, the 100 mg/20 mL (5 mg/mL) reconstituted solution should be further diluted to a fixed concentration of 1.25 mg/mL using 0.9% sodium chloride injection
- VEKLURY does not contain any preservatives. Once opened, **do not reuse or save reconstituted or diluted VEKLURY infusion solution**
- For detailed dose preparation instructions, please see full [Prescribing Information](#)

Reconstitution

- To reconstitute VEKLURY for injection, lyophilized powder, add 19 mL of Sterile Water for Injection using a suitably sized syringe and needle per vial
- Following reconstitution, the vial will contain 100 mg/20 mL (5 mg/mL) of VEKLURY solution

Dilution

- Dilute reconstituted product immediately in either a 100 mL or 250 mL 0.9% sodium chloride infusion bag
- For pediatric patients (birth to <18 years of age) weighing ≥ 1.5 kg to <40 kg, the 100 mg/20 mL (5 mg/mL) reconstituted solution should be further diluted to a fixed concentration of 1.25 mg/mL using 0.9% sodium chloride injection
 - Small 0.9% sodium chloride injection infusion bags or an appropriately sized syringe should be used for pediatric dosing
 - A syringe and syringe pump may be used for infusion volumes <50 mL
- It is always recommended to administer IV medication immediately after preparation when possible
- The prepared infusion solution is stable for 24 hours at room temperature (20 °C to 25 °C [68 °F to 77 °F]) or 48 hours at refrigerated temperature (2 °C to 8 °C [36 °F to 46 °F])
 - The prepared infusion syringe should be used immediately

IMPORTANT: This product does not contain any preservatives. Care should be taken to prevent inadvertent microbial contamination. Any unused reconstituted or diluted VEKLURY infusion solution should be discarded.

Please see full [Prescribing Information](#) for Veklury.

IMPORTANT SAFETY INFORMATION (cont'd)

Dosage and administration (cont'd)

- **Treatment duration** (cont'd):
 - For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended up to 5 additional days, for a total treatment duration of up to 10 days.
 - For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days.

Administration¹

Recommended rate of infusion for adult and pediatric patients weighing ≥ 40 kg[†]

Infusion bag volume	Infusion time	Rate of infusion
250 mL	30 minutes	8.33 mL/min
	60 minutes	4.17 mL/min
	120 minutes	2.08 mL/min
100 mL	30 minutes	3.33 mL/min
	60 minutes	1.67 mL/min
	120 minutes	0.83 mL/min

[†]For pediatric patients weighing ≥ 1.5 kg to < 40 kg, administer VEKLURY via intravenous infusion over 30 minutes to 120 minutes, the rate (mL/min) of which should be calculated based on the total infusion volume and total infusion time.

- Do not administer VEKLURY simultaneously with any other medication
- The compatibility of VEKLURY injection with IV solutions and medications other than 0.9% sodium chloride injection, USP, is not known
- Only administer VEKLURY via IV infusion over 30 minutes to 120 minutes
- For detailed administration instructions, please see full [Prescribing Information](#)

IMPORTANT SAFETY INFORMATION (cont'd)

Dosage and administration (cont'd)

• Treatment duration (cont'd):

- For patients who are **not hospitalized**, diagnosed with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 and within 7 days of symptom onset for outpatient use.

- **Testing prior to and during treatment:** Perform hepatic laboratory and prothrombin time testing prior to initiating VEKLURY and during use as clinically appropriate.
- **Renal impairment:** No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis. VEKLURY may be administered without regard to the timing of dialysis.

Pregnancy and lactation

- **Pregnancy:** A pregnancy registry has been established for VEKLURY. Available clinical trial data for VEKLURY in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following second- and third-trimester exposure. There are insufficient data to evaluate the risk of VEKLURY exposure during the first trimester. Maternal and fetal risks are associated with untreated COVID-19 in pregnancy.
- **Lactation:** VEKLURY can pass into breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from an underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Please see full [Prescribing Information](#) for Veklury.

The Centers for Medicare & Medicaid Services has assigned a permanent J-code, **J0248**, for VEKLURY® (remdesivir) when administered in an outpatient setting. This code has a 1-mg billing increment, is available for use by all payers, and is effective for dates of service on or after December 23, 2021.²

Effective April 1, 2022, the VEKLURY HCPCS code, J0248, has been assigned a pass-through status indicator under the hospital Outpatient Prospective Payment System.³

Coding requirements will vary by payer, setting of care, and date of service. Please verify patient-specific insurance benefits to confirm specific coding and billing guidelines for VEKLURY.

ADVANCING
ACCESS®

An Advancing Access® program specialist is available if you need further assistance, want more information, or have questions.

Call **1-800-226-2056**, M–F, 9 AM–8 PM ET

Please see full [Prescribing Information for Veklury](#).

For more information, [visit vekluryhcp.com](http://vekluryhcp.com).

HCPCS=Healthcare Common Procedure Coding System.

References: **1.** VEKLURY. Prescribing Information. Gilead Sciences, Inc.; 2024. **2.** Special Edition-COVID-19: new HCPCS code for remdesivir antiviral medication. News release. Centers for Medicare & Medicaid Services. January 7, 2022. Accessed April 12, 2024. <https://www.cms.gov/outreach-and-education/outreachffsprovpartprogprovider-partnership-email-archive/2022-01-07-mlnc-se> **3.** Centers for Medicare & Medicaid Services. Pub 100-04 Medicare Claims Processing. Accessed April 12, 2024. <https://www.cms.gov/files/document/r11305cp.pdf>



GILEAD

Veklury®
remdesivir 100 MG FOR
INJECTION

VEKLURY, the VEKLURY Logo, ADVANCING ACCESS, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies.

© 2024 Gilead Sciences, Inc. All rights reserved. US-VKYP-0665 06/24